ライフサイエンスコーパス: pneumococcus

1 te vaccine against Streptococcus pneumoniae (pneumococcus).

2 (e.g., multidrug-resistant tuberculosis and pneumococcus).

3 s species, such as Streptococcus pneumoniae (pneumococcus).

4 spiratory pathogen Streptococcus pneumoniae (pneumococcus).

5 sure during asymptomatic carriage (e.g., the pneumococcus).

6 t immunity, which may ultimately benefit the pneumococcus.

7 esponse to nasopharyngeal acquisition of the pneumococcus.

8 before FtsZ and guides septum positioning in pneumococcus.

9 e effectiveness of within host selection for pneumococcus.

10 a highly virulent, but immunogenic, form of pneumococcus.

11 cholesterol-dependent cytolysin produced by pneumococcus.

12 Influenza affects host susceptibility to pneumococcus.

13 swabs yielded an alternative serotype or no pneumococcus.

14 y recombinational loss, which is frequent in pneumococcus.

15 ed on RelA after instillation of LPS but not pneumococcus.

16 cific CDS when compared to the pan-genome of pneumococcus.

17 natural resistance and cellular immunity to pneumococcus.

18 arynx, the principal ecological niche of the pneumococcus.

19 ns than control subjects who did not acquire pneumococcus.

20 ed 5157 specimens, of which 3525 (68.4%) had pneumococcus.

21 against pulmonary challenge with serotype 3 pneumococcus.

22 nges seen after infection with the wild-type pneumococcus.

23 ly involved in the innate immune response to pneumococcus.

24 fatal infections was taking prophylaxis for Pneumococcus.

25 activity is important for transformation in pneumococcus.

26 cells was microbiologically demonstrated on Pneumococcus.

27 0) of those with positive blood cultures for pneumococcus.

28 an and infer its role in the division of the pneumococcus.

29 alleled in the incidence of OM due to non-VT pneumococcus.

30 relative change in incidence of OM due to VT pneumococcus.

31 ls exhibited increased opsonophagocytosis to pneumococcus (11.4% median increase) for approximately 3

32 6.11 [IQR, 20.41-76.28] FDA U/mL; P < .001), pneumococcus (17.24 [IQR, 11.33-40.25] mg/L vs 31.97 [IQ

33 vs 1.34 [IQR, 0.15-4.82] mg/L; P = .009) and pneumococcus (33.47 [IQR, 4.03-69.43] mg/L vs 50.84 [IQR

34 The dominant pathogen was pneumococcus (46.4%: 71/153) followed by meningococcus (

35 .7 [IQR, 27.9-168.4] FDA U/mL; P = .006) and pneumococcus (47.32 [IQR, 32.56-77.80] mg/L vs 14.77 [IQ

36 human pathogen Streptococcus pneumoniae (the pneumococcus)(6), which lacks the Min and the nucleoid o

37 ases were confirmed, predominantly caused by pneumococcus (98 [50.5%]).

38 Streptococcus pneumoniae (the pneumococcus), a leading cause of bacterial disease, is

39 nown about the diversity of phages among the pneumococcus, a leading global pathogen.

40 , and 6 (43%) of 14 with blood cultures grew pneumococcus, all serotype 5.

41 d animals, compared with those infected with pneumococcus alone.

42 virus) and 3 with nonviral pathogens (2 with pneumococcus and 1 with Cryptococcus species).

43 Introduction of vaccines against pneumococcus and Haemophilus influenzae type b (the most

44 l and severe pneumonia cases attributable to pneumococcus and Hib was ascertained with vaccine clinic

45 oportion of pneumonia deaths attributable to pneumococcus and Hib.

46 immune system in the interaction between the pneumococcus and host.

47 w insights into the synergistic link between pneumococcus and influenza virus in the context of otiti

48 be important in the interaction between the pneumococcus and its human host.

49 r findings shed light on the epidemiology of pneumococcus and may have notable implications for the c

50 ngs demonstrate that nasal colonization with pneumococcus and microaspiration prime AMs, leading to b

51 Interactions between the pneumococcus and other bacterial species alter carriage

52 nose on human glycoproteins that bind to the pneumococcus and protect the airway.

53 and selection in the population genomics of pneumococcus and provide proof of principle of the consi

54 thus discovered a novel interaction between pneumococcus and rBPI21, a potent antimicrobial peptide

55 -independent CCR mechanism identified in the pneumococcus and the first example of lethality from los

56 ation are likely to affect the spread of the pneumococcus and the rate of pneumococcal disease in the

57 s, leading to brisker responsiveness to both pneumococcus and unrelated bacterial pathogens.

58 olunteers that were naturally colonized with pneumococcus and, after clearance of their natural carri

59 of all strains of Streptococcus pneumoniae (pneumococcus) and induces antibodies which protect again

60 tween the pathogen Streptococcus pneumoniae (pneumococcus) and its human host is the ability of this

61 action between Streptococcus pneumoniae (the pneumococcus) and its human host.

62 RK (VicRK) TCSs of Streptococcus pneumoniae (pneumococcus) and other Streptococcus species show numer

63 reservoir for Streptococcus pneumoniae (the pneumococcus) and the source for both horizontal spread

64 y all serotypes of Streptococcus pneumoniae (pneumococcus), and all have been studied separately for

65 -shaped, ovococcal Streptococcus pneumoniae (pneumococcus), and depletion of GpsB leads to formation

66 ng 774 nonhospitalized UC, 185 (24%) yielded pneumococcus, and 70 (38%) were serotype 5.

67 colonized adults were given a type 23F or 6B pneumococcus, and a portion of these subjects became col

68 nged with WU2, a PspA(+) capsular serotype 3 pneumococcus, and its PspA(-) mutant JY1119.

69 ren globally against Haemophilus influenzae, pneumococcus, and meningococcus.

70 r a nonserotypeable isolate was or was not a pneumococcus, and the sequence of the ply gene fragment

71 ressed immunoglobulin G (IgG) levels and low pneumococcus antibody titers in a subset.

72 Noncapsular virulence factors on the pneumococcus are thought to facilitate this process by s

73 Antibodies to pneumococcus are thought to represent the primary mechan

74 Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality

75 The vp1 gene is widely distributed across pneumococcus as well as encoded in related species.

76 er, the method by which neutrophils kill the pneumococcus as well as other Gram-positive bacteria, is

77 The success of Streptococcus pneumoniae (the pneumococcus) as a pulmonary pathogen is related to its

78 R mechanism and an essential activity in the pneumococcus, as an HPr point mutation abolishing HPrK/P

79 1950, the proportion of pneumonia caused by pneumococcus began to decline.

80 n(19F)-14 (ST236) to 19A ST320 has made this pneumococcus better able to colonize of the nasopharynx.

81 thal intratracheal challenge with serotype 8 pneumococcus, but it does not promote polymorphonuclear

82 ction against the homologous serotype of the pneumococcus, but the efficacies of type-specific IgM an

83 but previous attempts to study this gene in pneumococcus by generating a dpr mutant were unsuccessfu

84 Detection of pneumococcus by lytA polymerase chain reaction (PCR) in

85 by the 11th day, and in lungs infected with pneumococcus by the 8th day.

86 These data suggest that the pneumococcus can alter flux of pyruvate metabolism depen

87 The pneumococcus can degrade a variety of complex glycans, i

88 The pneumococcus can metabolize a range of carbohydrates tha

89 ugh this has not been observed in nature, if pneumococcus can replace its cps with oral streptococcal

90 The prevalence of Streptococcus pneumoniae (pneumococcus) carriage is higher in adults who are infec

91 No pneumococcus cases were reported after pneumococcal and

92 Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pne

93 Streptococcus pneumoniae ('pneumococcus') causes an estimated 14.5 million cases of

94 Streptococcus pneumoniae (the pneumococcus) causes diseases from otitis media to life-

95 Streptococcus pneumoniae (pneumococcus) causes multiple infectious diseases.

96 Streptococcus pneumoniae (pneumococcus) causes respiratory and systemic infections

97 e immunized with heat-killed type 3 serotype pneumococcus cells are impaired in generating pneumococc

98 , we evaluate the role of lung microbiota in Pneumococcus colonization of the lungs.

99 Streptococcus pneumoniae (the pneumococcus) colonizes the human nasopharynx and can ca

100 Our results show that host-pneumococcus combination was at the core of observed var

101 ficant impairment of IgM humoral response to pneumococcus compared with controls (IgM titer 79.0 vs 2

102 quenced strains of Streptococcus pneumoniae (pneumococcus) contain a version of the blp locus which i

103 Streptococcus pneumoniae, also known as the pneumococcus, contains several surface proteins that alo

104 We hypothesized that the surface charge of pneumococcus contributes to its success in nasopharyngea

105 e CSP6.1, formerly reported as an "atypical" pneumococcus, CSPps1 to reflect its occurrence in S. pse

106 3 blinded nasopharyngeal specimens that were pneumococcus culture positive, the TAC pan-pneumococcus

107 The proportion of meningitis cases due to pneumococcus declined in the post-PCV era.

108 The proportion of ARI cases with pneumococcus detected among those with complete testing

109 th blood culture and UAT; 21.2% (72/340) had pneumococcus detected, yielding a baseline pneumococcal

110 or human metapneumovirus (hMPV) illness had pneumococcus detected.

111 th broad protection against meningococci and pneumococcus, develop an effective vaccine against group

112 subclasses (IgG1-4), and antibody titers to Pneumococcus, diphtheria, and tetanus.

113 mmunization may impact infant acquisition of pneumococcus during influenza infection.

114 sed to HIV become carriers of nasopharyngeal pneumococcus earlier and more frequently than infants wh

115 powerful strategy for the identification of pneumococcus either in pure cultures or in polymicrobial

116 or hepoxilin-A3, an eicosanoid required for pneumococcus-elicited neutrophil trans-epithelial migrat

117 We conclude that type 1 pilus expression in pneumococcus exhibits a bistable phenotype, which is dep

118 Pneumococcus-expressed pili are composed of three struct

119 Pneumococcus expresses EndA during growth.

120 Streptococcus pneumoniae (pneumococcus) expresses a capsular polysaccharide (CPS)

121 Streptococcus pneumoniae (pneumococcus) expresses multiple, surface-exposed, choli

122 c antibody titers and subsequent carriage of pneumococcus expressing a particular antigen variant.

123 TIGR4, a serotype 4 isolate, caused discrete pneumococcus-filled microscopic lesions (microlesions),

124 servation in relation to the aptitude of the pneumococcus for sustaining its human reservoir.

125 how genomics has transformed the use of the pneumococcus for the pursuit of new antibiotics, and mad

126 We assessed mortality from pneumococcus for three periods 1997-2001 (baseline), 200

127 Streptococcus pneumoniae (pneumococcus) frequently colonizes the human nasopharynx

128 IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals

129 Invasive disease, defined as isolation of pneumococcus from a sterile site, was identified in chil

130 ssing protein A (DprA) regulates the exit of pneumococcus from the competent state.

131 ing received immunizations for influenza and pneumococcus (from any source) (in 2000, 77% of MMC vs 6

132 the proportion of meningitis cases caused by pneumococcus, from 77.3% (17/22) in 2011 to 32.4% (11/34

133 rring SK95 cps into noncapsulated, avirulent pneumococcus gave it the capacity for virulence in a mou

134 These include pneumococcus, group B Streptococcus, Haemophilus influen

135 ain causes of PBM: Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and Neisseria men

136 Identification of Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and Neisseria men

137 These data suggest that the pneumococcus has a major role in the development of pneu

138 Pneumococcus has continued to decline; at present, this

139 To persist in the human host, the pneumococcus has developed strategies to evade opsonizat

140 quired immunity to Streptococcus pneumoniae (pneumococcus) has long been assumed to depend on the pre

141 IPD (pneumococcus identified from a normally sterile site) ca

142 emic patients lacked protective responses to Pneumococcus in 14/47 (30%), diphtheria in 15%, and teta

143 showed Cryptococcus in 64 (19.5%) patients, pneumococcus in 8 (2.4%), and meningococcus in 2 (0.6%).

144 investigated human neutrophil killing of the pneumococcus in a complement-dependent opsonophagocytic

145 variance effective population size (N(e)) of pneumococcus in a mouse colonization model by monitoring

146 eumonia (MCPP) was confirmed by detection of pneumococcus in a relevant normally sterile body fluid.

147 Ne was also evident for the colonization of pneumococcus in BALB/c mice exposed to cholera toxin 4 w

148 ethal intranasal infection with a serotype 8 pneumococcus in BALB/c mice.

149 ntratracheal challenge model with serotype 8 pneumococcus in C4 KO mice.

150 -control study tested whole blood by PCR for pneumococcus in children aged 1-59 months hospitalized w

151 gh prevalence of nasal colonization with the pneumococcus in children.

152 emic and pulmonary challenge with serotype 3 pneumococcus in immunized and control mice.

153 to implement vaccines against rotavirus and pneumococcus in LMICs, and the roll out of the MenAfriVa

154 In this Review, we discuss the role of pneumococcus in the disease continuum and assess clinica

155 s essential for the host defense response to pneumococcus in the lungs and that RelA in airway epithe

156 f culture and molecular methods in detecting pneumococcus in the nasopharynx of healthy individuals a

157 Use of qPCR improved detection of pneumococcus in the nasopharynx of healthy individuals.

158 es on immunizations, including varicella and pneumococcus in the post-vaccine era, use of a polyvalen

159 Despite routine vaccination against pneumococcus in the United States, this organism is stil

160 serum to rPstS did not inhibit growth of the pneumococcus in vitro, suggesting that antibodies do not

161 re shown to be present on the surface of the pneumococcus in vivo during pneumococcal pneumonia.

162 NTHi 86-028NP protected pneumococcus in vivo in both the effusion fluid and bull

163 complex, kills Streptococcus pneumoniae (the pneumococcus) in a manner that shares features with acti

164 The proportion of CAP cases attributable to pneumococcus increased from 27.1% to 52.5% using that cu

165 This observation demonstrates that the pneumococcus incurs a substantial fitness cost in order

166 oportion of pneumonia deaths attributable to pneumococcus indicate that as many as 118 000 (UR 69 000

167 ccumb to challenge with live type 3 serotype pneumococcus, indicating that TACI is required for T cel

168 of AIF-specific antiserum markedly impaired pneumococcus-induced apoptosis.

169 implications for prevention and treatment of pneumococcus-induced inflammation.

170 st, ERK pathway inhibitors failed to inhibit pneumococcus-induced iNOS protein accumulation.

171 though both pathways have been implicated in pneumococcus-induced neuronal cell death, their relative

172 pneumoniae in vivo, thus implicating HXA3 in pneumococcus-induced pulmonary inflammation.

173 L-6) mRNA levels peaked at 3 to 6 h for both pneumococcus-infected and NTHi-infected animals.

174 al, lower transcript levels were detected in pneumococcus-infected than in NTHi-infected animals.

175 utinin in the combined influenza A virus and pneumococcus infection cohort suggested that there were

176 have a crucial role in immunity to systemic pneumococcus infection, because both vaccinated wild-typ

177 ster of multiresistant invasive serogroup 19 pneumococcus infections, including two fatalities, was r

178 For prevention of Streptococcus pneumoniae (pneumococcus) infections in infancy, protein-conjugated

179 ith influenza virus and then challenged with pneumococcus, influenza viruses of any subtype increased

180 day after NTHi inoculation and 3 days after pneumococcus inoculation.

181 The pneumococcus is a diverse pathogen whose primary niche i

182 Pneumococcus is a diverse pathogen, with >90 serotypes,

183 Pneumococcus is a leading cause of pneumonia and meningi

184 The pneumococcus is a leading pathogen infecting children an

185 Pneumococcus is also a major cause of human ocular infec

186 ct of sustained PCV13 use and to monitor how pneumococcus is causing disease in the meningitis belt.

187 The pneumococcus is one of the longest-known pathogens.

188 We conclude that a suicide gene of pneumococcus is spxB, which induces an apoptosis-like de

189 Pneumococcus is the most common and aggressive cause of

190 Interestingly, pneumococcus is the only bacterium known to adhere to an

191 Streptococcus pneumoniae (the pneumococcus) is a common commensal inhabitant of the na

192 Streptococcus pneumoniae (the pneumococcus) is a common nasopharyngeal commensal that

193 Streptococcus pneumoniae (the pneumococcus) is a human pathogen, accounting for massiv

194 Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis

195 Streptococcus pneumoniae (pneumococcus) is a leading cause of infections worldwide

196 Streptococcus pneumoniae (pneumococcus) is a leading human respiratory pathogen th

197 Streptococcus pneumoniae (the pneumococcus) is a major cause of bacterial pneumonia, m

198 Streptococcus pneumoniae (the pneumococcus) is a major cause of mortality and morbidit

199 Streptococcus pneumoniae (the pneumococcus) is a major human pathogen and a leading ca

200 Streptococcus pneumoniae (pneumococcus) is a major human pathogen causing pneumoni

201 Streptococcus pneumoniae (pneumococcus) is a major human pathogen, which evolved n

202 Streptococcus pneumoniae (pneumococcus) is a major human pathogen.

203 Streptococcus pneumoniae (pneumococcus) is a pathogen that causes severe local and

204 Streptococcus pneumoniae (pneumococcus) is a principal cause of bacterial middle e

205 Streptococcus pneumoniae (pneumococcus) is a significant pathogen that frequently

206 Streptococcus pneumoniae (pneumococcus) is an opportunistic bacterial pathogen res

207 Streptococcus pneumoniae (pneumococcus) is an oval-shaped, symmetrically dividing

208 Streptococcus pneumoniae (pneumococcus) is both a widespread nasal colonizer and a

209 Streptococcus pneumoniae (the pneumococcus) is capable of invading the heart.

210 Streptococcus pneumoniae (the pneumococcus) is carried in the nasopharynx of healthy i

211 petence regulon of Streptococcus pneumoniae (pneumococcus) is crucial for genetic transformation.

212 s of the bacterium Streptococcus pneumoniae (pneumococcus) is its transmission from host to host, the

213 pulmonary pathogen Streptococcus pneumoniae (pneumococcus) is required for both genetic transformatio

214 Streptococcus pneumoniae (the pneumococcus) is the leading cause of community-acquired

215 Streptococcus pneumoniae (pneumococcus) is the primary cause of bacterial meningit

216 Streptococcus pneumoniae (the pneumococcus) is the world's foremost bacterial pathogen

217 a-associated hospitalizations and IPP cases (pneumococcus isolated from normally sterile sites with d

218 e opaque phenotype was predominant among the pneumococcus isolates from the middle-ear fluid in the c

219 andard microbiological methods were used for pneumococcus isolation and serotyping.

220 man mAbs to the major surface antigen of the pneumococcus, its capsular polysaccharide, and tested th

221 atory tract of mice with influenza virus and pneumococcus leads to synergistic stimulation of type I

222 ecimens but also by the misidentification of pneumococcus-like viridans group streptococci (P-LVS) as

223 e pneumococcus culture positive, the TAC pan-pneumococcus lytA assay was positive in 21 (91% sensitiv

224 The outer cell surface of pneumococcus may assume various degrees of negative char

225 rate that morphological heterogeneity in the pneumococcus may promote colonization of the upper respi

226 Pneumococcus, meningococcus, and H. influenzae accounted

227 Phenotypic detection of pneumococcus, meningococcus, and H. influenzae was confi

228 ues were performed to detect the presence of pneumococcus, meningococcus, and H. influenzae.

229 Pneumococcus, meningococcus, and Haemophilus influenzae

230 ewborns represent a consistent population of pneumococcus-naive individuals in which to estimate the

231 data, which underscore the plasticity of the pneumococcus, need to be confirmed with in vivo analyses

232 of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by government

233 Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), a

234 eillance targeting Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), a

235 Identification of Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), a

236 ch serine protease is sufficient to kill the pneumococcus, none is essential.

237 gen test, or whole-blood lytA rtPCR revealed pneumococcus or if lytA rtPCR from NP swabs gave a resul

238 nations (OR, 4.25; 95% CI, 2.10-8.60), adult pneumococcus or tetanus vaccinations (OR, 5.14; 95% CI,

239 than in those who were culture negative for pneumococcus (P<.05).

240 Colonization with pneumococcus (PNC), which primes for memory cell respons

241 e important in predicting how changes in the pneumococcus (Pnc)-specific B-cell repertoire will influ

242 l reduction in the number of LRT samples and pneumococcus-positive cultures and significant changes i

243 The prevalence of pneumococcus-positive samples was highest at onset of IL

244 AIT) cells against in vitro stimulation with pneumococcus prior to challenge associated with protecti

245 Streptococcus pneumoniae (pneumococcus) produces hydrogen peroxide as a by-product

246 Streptococcus pneumoniae (pneumococcus) produces many capsule types that differ in

247 These patients should receive lifelong pneumococcus prophylaxis.

248 regation, and division site selection in the pneumococcus, providing a simple way to ensure equally s

249 The Scottish Meningococcus and Pneumococcus Reference Laboratory (SMPRL) provides a nat

250 The competence regulon of pneumococcus regulates both genetic transformation and v

251 We assessed the effect of PCV13 use on pneumococcus-related admissions to hospital 2 years afte

252 echanisms underlying the lethality caused by pneumococcus remain elusive.

253 e vaccine era, Streptococcus pneumoniae (the pneumococcus) remains a leading cause of otitis media, a

254 Streptococcus pneumoniae (pneumococcus) remains a significant health threat worldw

255 Pneumococcus resists beta-lactams by expressing variants

256 between a respiratory virus protein and the pneumococcus resulting in increased bacterial virulence

257 mes caused by Haemophilus influenzae type b, pneumococcus, rotavirus, and early infant influenza.

258 transporter is likely unique and integral to pneumococcus's strategy of carbon catabolite repression

259 rom bacterial carriage to infection with the pneumococcus serving as a model organism.

260 ch as the pathogen Streptococcus pneumoniae (pneumococcus), side-wall (peripheral) peptidoglycan (PG)

261 ruption in IgA expression, it was found that pneumococcus-specific IgA played a significant role in t

262 Pneumococcus (Streptococcus pneumoniae) remains a signif

263 of pneumonic lesions, using a bioluminescent pneumococcus, suggested that the effect of NA inhibition

264 ant from degranulated neutrophils killed the pneumococcus, suggesting a role for granular products.

265 In addition, pneumococcus synthesizes copious amounts of AcP and hydr

266 spiratory pathogen Streptococcus pneumoniae (pneumococcus) synthesizes AcP by the conventional pathwa

267 er in children who were culture positive for pneumococcus than in those who were culture negative for

268 In the pneumococcus, the coordinated secretion of pili from the

269 As discussed here in the context of the pneumococcus, the study of PavB highlights the central r

270 Hydrogen peroxide is produced by the pneumococcus through the action of pyruvate oxidase (Spx

271 ty by tyrosine phosphorylation may allow the pneumococcus to adapt to the requirements of both coloni

272 Bacterial mutations predisposing pneumococcus to causing meningitis, a more severe form o

273 We conclude that PspA and PspC help the pneumococcus to evade complement attack by binding C4BP

274 mplex regulation of pneumocins may allow the pneumococcus to reserve the secretion of active peptides

275 about the biological changes that permit the pneumococcus to switch from asymptomatic coloniser to in

276 man pathobiont Streptococcus pneumoniae (the pneumococcus) to cause severe invasive infections.

277 In Streptococcus pneumoniae (pneumococcus), transformation occurs when cells enter co

278 covalently to the surface polysaccharides of pneumococcus type 14, Shigella flexneri type 2a, and Esc

279 mutation in either comC or luxS rendered the pneumococcus unable to produce early biofilms on HREC.

280 l surface and the overlying mucus layer, the pneumococcus undergoes micro-invasion of the epithelium

281 We investigated how the pneumococcus utilizes these enzymes to metabolize differ

282 es tested were naive responses to rabies and pneumococcus vaccines, delayed-type hypersensitivity ski

283 ral Streptococcus strains can make acapsular pneumococcus virulent, and interspecies cps transfer sho

284 Pneumococcus was considered the cause of CAP in HIV-infe

285 Pneumococcus was detected by lytA rtPCR from sputum in 1

286 Nasopharyngeal carriage prevalence of pneumococcus was monitored in prospective studies of Bed

287 Type 3 pneumococcus was more commonly isolated from patients wi

288 Pneumococcus was not detected in the blood of D11-treate

289 Pneumococcus was responsible for most infections (67.3%:

290 Pneumococcus was the main pathogen responsible for PBM,

291 Type 3 pneumococcus was the most commonly identified serotype.

292 When acapsular pneumococcus was transformed with SK95 cps, the transfor

293 e variation in Streptococcus pneumoniae (the pneumococcus) was investigated.

294 NTHi 86-028NP bla and pneumococcus were both recovered from the surface-associ

295 ved from choline-binding protein A (CbpA) of pneumococcus were identified and then genetically fused

296 imals, and animals infected with listeria or pneumococcus, were 2.3, 2.5, and 2.6, respectively.

297 much greater C3 deposition onto the PspA(-) pneumococcus when exposed to normal mouse serum from wil

298 e supernatant (CCS) from a type 14 strain of pneumococcus which contained secreted pneumococcal prote

299 synergism exists between influenza virus and pneumococcus, which likely accounts for excess mortality

300 (PG) synthesis in Streptococcus pneumoniae (pneumococcus); yet, mechanisms of this switching remain